At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Effectively assessing anemia in myelofibrosis goes beyond hemoglobin levels, and should focus on symptoms, daily function, and quality of life to guide treatment. In a recent discussion, Raajit Rampal ...

Academic-center care was independently associated with higher complete oncologic resection rates and improved overall survival versus nonacademic facilities after adjustment for age, comorbidity, and ...

Overall survival similarly tracked tumor shrinkage, with 4-year OS of 84.3% (CR), 67.4% (PR1), 55.6% (PR2), 41.6% (PR3), 29.2% (SD), and 20.0% (PD). Median DOR was not reached in CR, approximately 22 ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

The randomized, double-blind, placebo-controlled, multicenter study enrolled 992 patients globally. The intent-to-treat ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.